• Samir Al-Adawi, Heather Hoaglin, Fariba Vesali, Atsu S S Dorvlo, and David T Burke.
• Department of Behavioral Medicine, College of Medicine & Health Sciences, Sultan Qaboos University, PO Box 35, Al-Khoudh 123, Muscat, Sultanate of Oman. adawi@squ.edu.om
• Brain Inj. 2009 Jun 1; 23 (6): 559-65.

BackgroundA previous study suggested that the routine use of drugs intended to improve attention and arousal, such as methylphenidate, tend to have a variable but not significant effect on sleep-wake cycles. As amantadine is a frequently employed drug in brain injury rehabilitation, with known effects on fatigue and motor processing speed, this study examined the effect of amantadine on the sleep-wake behaviour of patients with brain injury undergoing rehabilitation.MethodThis was a naturalistic observation using an observationally defined sleep-wake distribution for a total of 43 subjects with brain injury. Identified patients were observed for a full 24 hours a day 2 weeks before and 2 weeks after starting amantadine. Some of these patients (n = 12) had been administered amantadine on clinical grounds and, for this paper, served as the experimental group, while the drug naive (n = 31) served as a control. Three outcome measures were operationalized: hours of sleep in 24 hours, hours of sleep during daytime and hours of sleep during night-time.ResultThe average number of hours of sleep during a 24-hour period was not significantly different for the two cohorts. Similarly hours of sleep during daytime and hours of sleep during night-time were on average the same for the two groups. The data suggest that amantadine has no direct bearing on sleep/wake cycles using these parameters.ConclusionThis study fails to demonstrate that the use of amantadine on an inpatient brain injury population will affect sleep/wake quantity.

27 keywords...

hide…